A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Trial Profile

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 18 Jul 2018 According to Immunomedics media release, Based on data from this study the U.S. Food and Drug Administration (FDA) has accepted the Companys Biologics License Application (BLA) for filing and granted Priority Review for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).The PDUFA target action date is January 18, 2019.
    • 05 Jun 2018 Results assessing the efficacy of sacituzumab govitecan in HR+/ HER2 negative mBC pts who had ≥ 1 prior hormonal therapy (n=54) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2018 Results presented in the Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top